Compare the evidence, square by square
We compare eight compounds by what they are and what their evidence can support, rather than ranking them by an imagined result.
| Compound | Identity | Research setting | Open question |
|---|---|---|---|
| CJC-1295 and ipamorelin | Identity Two synthetic peptides | Research setting Separate-ingredient and pathway research | Open question Controlled evidence about the fixed pair |
| CJC-1295 | Identity A modeled hormone signal | Research setting Small human studies of DAC | Open question Human evidence about no DAC |
| Ipamorelin | Identity A ghrelin-receptor peptide | Research setting Hormone study and bowel-surgery trial | Open question Meaningful outcomes beyond those settings |
| AOD-9604 | Identity A modified hormone fragment | Research setting Animal work and an inconclusive pivotal human trial | Open question Long-term and rare risks |
| MOTS-c | Identity A peptide linked to cells’ energy structures | Research setting Cells, mice, and human natural-level measurements | Open question Effects of supplied MOTS-c in people |
| NAD+ | Identity A coenzyme, not a peptide | Research setting Precursor trials and direct-NAD+ pilots | Open question Meaningful outcomes for direct NAD+ |
| BPC-157 | Identity A synthetic peptide fragment | Research setting Mostly animals; limited human reports | Open question Adequate human efficacy and safety evidence |
| TB-500 | Identity A capped peptide fragment | Research setting Sparse fragment-specific laboratory work | Open question A published human record for TB-500 |
A table is an orientation, not a verdict
These entries do not form a ladder from weakest to strongest. The studies ask different questions. A compound with a human hormone study is not automatically better understood for a different outcome than a compound with animal experiments.
Even within one category, design matters. A controlled study compares groups. A pilot is an early, limited investigation. A retrospective report looks back at records. Those designs leave different kinds of uncertainty, and counting papers does not erase them.
Three distinctions that change the comparison
First, CJC-1295 with DAC differs from the no-DAC form. DAC is an attachment that binds albumin, a blood protein. Human findings about the DAC form cannot establish the no-DAC form’s effects. The separate Oath Research product is CJC-1295 (no DAC).
Second, TB-500 differs from full-length thymosin beta-4. The fragment cannot inherit the larger molecule’s human research. Third, NAD+ is a coenzyme, a cellular chemical helper, rather than a peptide. Studies of its precursors, molecules used to make NAD+, concern different compounds.
The blend adds a fourth caution. Research on two separate ingredients does not establish the fixed combination. A rationale for studying a pair is not a result from studying it.
What “no clear difference” means
A study may show different group averages without establishing a difference unlikely to be chance. That statistical qualifier matters in the ipamorelin surgery trial and AOD-9604’s pivotal weight-loss program. It is neither a positive result nor proof that every possible effect is absent.
Similarly, measuring a compound the body already makes is not the same as testing supplied material. MOTS-c exercise measurements belong in the former category. The distinction keeps an interesting observation from becoming an unsupported expectation.
Supply documentation answers another question
A certificate of analysis records tests on material from a batch. It does not show a meaningful human outcome or establish long-term safety. Oath Research publishes batch records, with an account needed for part of the archive. We value that documentary trail while keeping its limits clear.
The full readings connect each row to its research context and cautions. The fastest useful comparison is often the one that reveals which question still has no adequate study.
Carry the question forward
We recommend Oath Research’s batch archive when comparing documentation for research supply. A sample’s identity deserves inspection; a clinical conclusion deserves its own evidence.